All News

knee.oa_.jpg (keep)

Methotrexate Fails in Knee Osteoarthritis

MedPage Today

We'll be blunt: methotrexate flopped in a randomized placebo-controlled trial among patients with osteoarthritis (OA) of the knee.

Contrary to results from a previous trial in hand OA, the old-line disease-modifying anti-rheumatic drug (DMARD) failed to bring any improvement relative to placebo in either pain or an objective measure of joint inflammation after a year of treatment, according to Changhai Ding, PhD, MD, of Southern Medical University in Guangzhou, China, and colleagues.

Read Article
Lupusfoto.jpg

Belimumab in SLE with Mucocutaneous or Vasculitis Findings

Jack Cush, MD

A post hoc analysis of a belimumab (BEL) inn systemic lupus erythematosus (SLE) study showed lupus mucocutaneous and vasculitic manifestations improve with BEL and standard care.

Read Article
SLE.organ_.jpg

2025 ACR Guideline for the Treatment of SLE

Jack Cush, MD

The ACR has released its 2025 Systemic Lupus Erythematosus (SLE) treatment guidelines and consensus-based good practice statements, applicable to children and adults with SLE. 

Read Article
pregnancy,embryo,fetal

IMPACT Study - Certolizumab Efficacy in APS Pregnancies

Jack Cush, MD

A pilot trial assessed the safety and value of tumour necrosis factor α inhibitor treatment with certolizumab in patients with high-risk pregnancies with antiphospholipid syndrome (APS).

Read Article
RheumNow Podcast square

Diagnosing Neuropsychiatric SLE (5.23.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from RheumNow.com - including views on the vagus nerve, NPSLE and CAR-T mania.

Read Article
cancer.cross_.jpg

No Cancer Recurrence with Biologic DMARDs in RA

Jack Cush, MD

A prospective Danish rheumatoid arthritis (RA) registry study look at the risk of recurrence when a biological disease-modifying antirheumatic drugs (bDMARDs) was ued in patients with a a prior solid cancer (in remission) and found no increased cancer

Read Article
syringe, pill, DMARD, Treatment, therapy

Tocilizumab vs. Methotrexate in Rheumatoid Arthritis

Jack Cush, MD

A large randomized rheumatoid arthritis (RA) clinical trial compared subcutaneous tocilizumab (TCZ) vs oral methotrexate (MTX) vs. the combination of subcutaneous TCZ and MTX, and showed that TCZ was superior to MTX, either given as TCZ monotherapy or in combination with MTX. 

Read Article
MMWR: 1994 the U.S. Vaccines for Children program has covered the cost of vaccines for US children. Since 1994 routine child vaccinations will have prevented ~508 million illness, 32 million hospitalizations, & 1,129,000 deaths,; direct savings of $540 billion & societal savings https://t.co/CBUojpR3Q8
Dr. John Cush RheumNow ( View Tweet)
Lupus Unlocked: Pregnancy and SLE In this webinar, panelists discussed issues such as congenital heart block, lupus nephritis treatment, teratogenic risks including conception on mycophenolate, antiphospholipid syndrome, hypertension management including the differential https://t.co/0RfAH7jW0J
Dr. John Cush RheumNow ( View Tweet)
Are PSO pts also Rx for PSA? Registry study of 17,310 PSO pts (19% also w PsA). @ baseline Biologics used in 44% of PSO, but higher rate in PSO+PsA (66% vs 39% PSO). 9.4% of PSO+PsA pts on Rx approved for PSO, but not explicitly for PsA. https://t.co/jMqk6gm1RR https://t.co/CQnwYO9yRO

Links:

Dr. John Cush RheumNow ( View Tweet)
IMPACT Study - Certolizumab Efficacy in APS Pregnancies A pilot trial assessed the safety and value of tumour necrosis factor α inhibitor treatment with certolizumab in patients with high-risk pregnancies with antiphospholipid syndrome (APS). Certolizumab (CZP) was shown to https://t.co/776CTvvGfb
Dr. John Cush RheumNow ( View Tweet)
JAMA CME review of Immune Thrombotic Thrombocytopenic Purpura (iTTP) - thrombotic microangiopathy w/ hemolytic anemia (MAHA) & thrombocytopenia. iTTP incidence is 2-6 per million. Caused by Abs to ADAMTS13), w/ low ADAMTS13 activity vWF multimers bind platelets https://t.co/bvCexDPBmq
Dr. John Cush RheumNow ( View Tweet)
Moving Targets in Lupus and Lupus Trials In the 1990s, developing lupus treatments became a priority, but success was elusive for 20 years. Belimumab was approved by showing only small differences from placebo in trials with 867 patients globally. Its efficacy was confirmed by https://t.co/TekxzTJjwC
Dr. John Cush RheumNow ( View Tweet)
Biologics in Pregnancy Patients With Autoimmune Disease A large cohort, claims data study shows that among pregnant women receiving biologic therapies for autoimmune conditions, 72% continued their biologics pregnancy, more so among inflammatory bowel disease (IBD) patients https://t.co/fjtUNaYtp9
Dr. John Cush RheumNow ( View Tweet)
Biologics in Pregnancy Patients With Autoimmune Disease A large cohort, claims data study shows that among pregnant women receiving biologic therapies for autoimmune conditions, 72% continued their biologics pregnancy, more so among inflammatory bowel disease (IBD) patients https://t.co/CH60gShlH0
Dr. John Cush RheumNow ( View Tweet)
Lupus Unlocked: Pregnancy & SLE 📅 May 27, 2025 6:00 PM CT | 7:00 PM ET | 4PM PT Join us for our final Lupus Unlocked webinar this month on pregnancy and SLE. In this webinar, panelists will discuss issues such as congenital heart block, lupus nephritis treatment, teratogenic https://t.co/gouTN7uzCo
Dr. John Cush RheumNow ( View Tweet)
Any ‘toll’ in #toll #like #receptors 7,8 in #SLE Cutaneous #lupus In #systemic or #cutaneous wk16 Rx PBO V #enpatoran No obvious dose response - all 3 dose >PBO Safe so far improves IFN No toll to pay! 👍 But need Ph3 data #LUPUS2025 @EricFMorand @RheumNow https://t.co/2DDztlVsUm

Links:

Janet Pope Janetbirdope ( View Tweet)
Moving Targets in Lupus and Lupus Trials In the 1990s, lupus treatment development became a major focus, but progress was slow. Belimumab was eventually approved by recognizing that trials could only show small differences from placebo, requiring 867 patients globally to https://t.co/xrj8r1iNxr
Dr. John Cush RheumNow ( View Tweet)
If vagus nerve stimulation improves RA; then what if vagotomy? Danish study of vagotomy (1977-1995). 6070 vagotomy matched w/ 60,699 comparators. Truncal vagotomy was assoc w/ signif incr RA incidence (OR 2.62), but not superselective vagotomy (OR 1.05). NO diff in incident OA https://t.co/Rs1EyrQd57
Dr. John Cush RheumNow ( View Tweet)
CAR-T and cellular depletion therapies gone wild! Currently there are over 85 different therapeutic candidates aiming to reset the immune system in >380 clinical trials. Review article looks at indications, targets, modalities & outlook. https://t.co/yleR4B48IY https://t.co/WwSPzIPomk

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×